产品名称

GDC 0980 - RG 7422 | GNE 390 | Apitolisib

产品货号

Axon 1782 CAS [1032754-93-0] MF C23H30N8O3SMW 498.60 Purity: 99% Soluble in DMSO Description Selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 α, β, δ and γ isoforms and apparent Ki of 17.3 nM for human mTOR. GDC-0980 has excellent pharmacokinetic and pharmaceutical properties and demonstrates broad activity in xenograft cancer models (breast, ovarian, lung, and prostate) References Certificates Categories Extra info JJ Wallin et al. GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway. Mol. Cancer Ther. 2011, 10(12), 2426-2436. AJ Wagner et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29 (suppl; abstr 3020). DP Sutherlin et al. Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer. J. Med. Chem. 2011, 54(21), 7579-87. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology PI3K mTOR PI3K-Akt-mTOR EC 2.7.11.1 Dual PI3K and mTOR inhibitor Chemical name (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one Parent CAS No. [1032754-93-0] Order Size Unit Price Stock 5 mg €105.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

GDC 0980 - RG 7422 | GNE 390 | Apitolisib

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 1782

CAS [1032754-93-0]

MF C23H30N8O3S
MW 498.60

Purity: 99%
Soluble in DMSO

GDC 0980

Description

Selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 α, β, δ and γ isoforms and apparent Ki of 17.3 nM for human mTOR. GDC-0980 has excellent pharmacokinetic and pharmaceutical properties and demonstrates broad activity in xenograft cancer models (breast, ovarian, lung, and prostate)